MyoKardia, Inc. News
Bristol-Myers Shares Gain After Positive Data From Opdivo Lung Cancer Trial
Bristol-Myers said its blockbuster drug, Opdivo, as well as chemotherapy helped patients suffering from resectable non-small cell lung cancer in a late-stage trial.
Morning Bell With Jim Cramer: Wait to Buy Regeneron
Jim Cramer shares stock market news about buying Regeneron stock, the Bristol Meyers deal, and Trump’s tweet about a stimulus package.
Stocks Close Higher; Trump Says He's Leaving Hospital Monday
Stocks end higher after President Trump tweets he's leaving Walter Reed Medical Center on Monday evening.
Is Bristol-Myers a Buy After $13.1 Billion Buy of MyoKardia?
MyoKardia is surging after a takeout deal from Bristol-Myers Squibb, which is marginally higher on the day. Does the deal make Bristol-Myers a buy?
Bristol-Myers Agrees To Buy Heart Treatment Maker MyoKardia for $13.1 Billion
MydoKardia's experimental heart treatment, Mavacamten, was granted a "breakthrough therapy designation' from the U.S. Food & Drug Administration in July of this year.
Moderna, MyoKardia Are Among Cutting-Edge Biotech Stocks for 2019
Moderna only went public in December, and is already creating a buzz.
We Want Bad News, Bears: Cramer's 'Mad Money' Recap
Jim Cramer says we actually want some bad news because definitive weaker news now drives stocks up and strong news takes them down.
Rocket Stocks Look Better on Re-Entry: Cramer's 'Mad Money' Recap
Jim Cramer looks at the high-flying FANG stocks, and says he likes these companies best when their prices return to earth.
Trump's Potential Return to Twitter Under Musk Hits Digital World
Digital World Acquisition, a company attempting to merge with former President Donald Trump's media group Truth Social, faces a new challenge.
Bluebird Bio's 2nd Approval Doesn't Guarantee Survival
Investors hoping for a revival at the struggling biotech might want to temper their expectations.